Multimodal prehabilitation as strategy for reduction of postoperative complications after cardiac surgery: a randomised controlled trial protocol

Miquel Coca-Martinez,1 Antonio Lopez-Hernandez,1 Mar Montane-Muntane,1 Maria Jose Arguis,1,2 Elena Gimeno-Santos,2,3 Ricard Navarro-Ripoll,1 Juan Perdomo,1 Manuel Lopez-Baamonde,1 Jose Rios,2,4 Jorge Moises,5 Maria Sanz de la Garza,5 Elena Sandoval,7 Barbara Romano,6 Raquel Sebio,3 Fernando Dana,3 Graciela Martinez-Pall1,2

ABSTRACT

Introduction Prehabilitation programmes that combine exercise training, nutritional support and emotional reinforcement (multimodal prehabilitation) have demonstrated efficacy reducing postoperative complications in the context of abdominal surgery. However, such programmes have seldom been studied in cardiac surgery, one of the surgeries associated with higher postoperative morbidity and mortality. This trial will assess the feasibility and efficacy in terms of reduction of postoperative complications and cost-effectiveness of a multimodal prehabilitation programme comparing to the standard of care in cardiac surgical patients.

Methods and analysis This is a single-centre, randomised, open-label, controlled trial with a 1:1 ratio. Consecutive 160 elective valve replacement and/or coronary revascularisation surgical patients will be randomised to either standard of care or 4–6 weeks of multimodal prehabilitation that will consist in (1) two times/week supervised endurance and strength exercise training sessions, (2) promotion of physical activity and healthy lifestyle, (3) respiratory physiotherapy, (4) nutrition counselling and supplementation if needed, and (5) weekly mindfulness sessions. Baseline, preoperative and 3-month postoperative data will be collected by an independent blinded evaluator. The primary outcome of this study will be the incidence of postoperative complications.

Ethics and dissemination This study has been approved by the Ethics Committee of Clinical investigation of Hospital Clinic de Barcelona (HCB/2017/0708). The results will be disseminated in a peer-reviewed journal.

Trial registration number NCT03466606.

INTRODUCTION

Background and rationale

Patients undergoing cardiac surgery are the most likely to have complications (more than 20%) and to die within the perioperative period (5.5% perioperative mortality in Spain).1 The occurrence of postoperative complications and the risk of death are mainly conditioned by the magnitude of the surgical stress and by the patient’s functional status, which is frequently conditioned by the presence of comorbidities.2 Despite the great advances that cardiac surgery and postoperative care have accomplished in the last decades, perioperative morbidity and mortality continue to be significant; mainly due to the increase of surgical indications in high-risk populations, older patients and patients with multiple comorbidities. The proportion of patients referred to cardiac surgery aged more than 75 years has risen from 16% in 1990 to 25%, as shown in recent studies.3 Postsurgical complications have undeniable impact in quality of life, short-term and middle-term survival and economical cost.1,5 Many studies have demonstrated the association between frailty and morbidity, mortality and hospital length of stay.6 Frailty is defined as a state of major vulnerability to stressors which usually goes with sarcopenia, reduced strength, resistance and level of physical activity.7 It is estimated that 25%–50% of the...
candidates to cardiac surgery are frail. Frailty has been associated with a twofold to threefold increased risk of mortality and major morbidity after cardiac surgery and increased healthcare costs.7,8

Patients referred to cardiac surgery usually present a significant reduction in their functional capacity, which is multifactorial. The cardiovascular disease itself and its associated symptoms such as dyspnoea or angina pectoris, respiratory comorbidities, anaemia, malnourishment, muscle mass loss, depression or anxiety can be found among the factors causing a decline in functional capacity.9–12 All of the aforementioned factors induce a tendency to physical inactivity which further deteriorates functional capacity. This deconditioning places the patients at a higher risk of postoperative morbidity and mortality, complicating the recovery phase as well. A recent study in patients referred to oncological abdominal surgery showed that the preservation of physical activity was the only factor independently associated to lower operative complications and postoperative recovery after major surgery.8,14,15 During the waiting period especially for surgery, physical inactivity is frequently more marked due to the fear that physical activity may exacerbate symptoms and also due to surgical anticipatory anxiety. Consequently, during this time span, there is a progressive deterioration in functional capacity which is not only reflected by a significant mortality rate among patients who are on the wait list but also by a prolongation of the patients’ recovery.16 This prolonged postoperative period causes an increase in hospital length of stay, medication administration and delays patients’ return to daily activities. Therefore, it has an impact on patients’ quality of life and also on healthcare costs.17

The aim of preoperative identification of the high-risk candidates to cardiac surgery is the development of strategies to optimise their health status and functional capacity prior to surgery.17 Prehabilitation emerges as a promising preventive intervention18–20 carried out during the presurgical period, while the patient is on the waiting list. It integrates a programme of supervised physical exercise training, nutritional counselling and supplementation, and psychological support.20,21 The goal of physical exercise training is to increase the patient’s functional capacity in order to increase their physiological resistance to surgical stress. Nutritional counselling is an essential complement to physical exercise training in as much as it guides patients in losing weight if needed, promotes anabolism and it ensures adequate protein intake to counteract the catabolism induced by exercise training.22 Psychological support is a useful tool to reduce perioperative anxiety and depression, which in turn increases patient engagement to physical exercise.23 Then, prehabilitation would provide an approach, through risk reduction therapies and promotion of heart healthy behaviours, potentially beneficial preoperatively and postoperatively.

Although there is robust evidence regarding the effectiveness of prehabilitation in patients undergoing abdominal oncological surgery,18,24–26 the role of prehabilitation programmes on reducing undesirable perioperative events has been assessed to a smaller extent in patients undergoing cardiac surgery. Arthur et al27 showed the efficacy of a multidimensional intervention in terms of intensive care unit (ICU) and hospital length of stay after coronary artery bypass grafting (CABG). However, this study was carried out in a group of low-risk patients and it did neither describe the preoperative intervention nor its impact on functional capacity. Even though the existing evidence hints at a beneficial effect of prehabilitation in cardiac surgery, the available literature is limited to low-risk patients and presents high heterogeneity on the intervention performed.28–30 This is a barrier to large-scale implementation of prehabilitation programmes in candidates to cardiac surgery.

Objectives

The general aim of this study is to investigate whether multimodal prehabilitation is effective in reducing postoperative complications in patients undergoing elective coronary revascularisation and/or valve replacement surgery.

Secondary outcomes will include: severity of postoperative complications, impact of prehabilitation on functional capacity, anxiety and depression, physical activity, hospital length of stay, ICU stay and readmission rate and a cost-effectiveness analysis.

Trial design

The trial protocol was written following the Standard Protocol Items: Recommendations for Interventional Trials guidelines.31 This is a prospective, randomised, open-label, controlled trial with allocation ratio 1:1 comparing standard of care versus 4–6 weeks of a multimodal prehabilitation programme. The recruitment period is scheduled from March 2018 to January 2021. Both primary end-point and baseline data will be blindly assessed. Intention-to-treat criteria will be used in order to define the analysis population; all randomised patients will be included in the analysis according to assigned group. The study protocol and informed consent have been evaluated and accepted by the Medical Research Ethics Committee at Hospital Clinic de Barcelona (2017/0708). The trial will be conducted according to the rules of Good Clinical Practice.

METHODS AND ANALYSIS

Setting

This trial will be conducted in a single academic tertiary hospital in Barcelona, Spain (Hospital Clínic de Barcelona). Assessments and study interventions will be performed at the outpatient ambulatory infrastructure of Hospital Clinic
de Barcelona. Surgery and postoperative hospitalisation will take place in the aforementioned hospital.

Eligibility criteria
Inclusion criteria
Patients older than 18 years old scheduled for CABG and/or valve surgery, with an expected waiting time before surgery of 6 weeks or more and that accept to participate in this clinical trial.

Exclusion criteria
Functional or anatomical physical impairment that makes it impossible to complete the assessments and the prehabilitation programme, determined by an experienced physiotherapist in cardiopulmonary rehabilitation; cognitive impairment that would impede understanding of study procedures, informed consent or study questionnaires; cardiac instability; dynamic left ventricle outflow tract obstruction, proven exercise induced arrhythmias; other comorbidities that imply clinical instability; patient refusal to participate in the study or impossibility to attend supervised training sessions. Specifically, we will not exclude patients with severe pulmonary hypertension or severe valvular stenosis.

Study outline
Participant screening, recruitment, randomisation and informed consent (T-1)
Participant selection will begin after surgery is proposed by the cardiac surgeon and a referral for preoperative evaluation is done. Within 1 week of the referral patient will be seen by an anaesthesiologist who will screen for eligibility criteria and will explore the willing of participating in a study related with cardiopulmonary reserve and postoperative outcome. If eligibility criteria are met, patient will be approached by a research medical staff involved in the trial. The research medical staff in charge of obtaining informed consent will randomise prior to meeting with the patient and proposing study participation.

Participants will be randomised with 1:1 ratio by a computer-generated sequence using Macro-SCReN software V.4.8.1.8302 (2018 Elsevier).

Baseline assessment (T0)
After signing the informed consent all participants will undergo a full blinded baseline medical, functional, nutritional and psychological assessment. Allocation to study group will be revealed to the part of the research team that will carry out the intervention once baseline assessment is completed. The functional capacity assessment will be conducted by a physiotherapist on different days to avoid fatigue related to it, and will consist in a standard incremental cardiopulmonary exercise testing on cycloergometer (CPET), where physiological variables in response to exercise and workload in watts (W) will be measured at the anaerobic threshold and at VO₂ peak. 35–38 Endurance time (ET) 33 in seconds will be measured by a cycling constant work-rate exercise test performed at a load equivalent of 80% of the peak workload (PWR) the patient could tolerate on the incremental CPET (Ergoline 900, Ergoline, Bitz, Germany and Ergocard Professional, Medisoft, Sorinnes, Belgium). It will detect the responsiveness of interventions in terms of improved exercise capacity. Participants will also undergo hand grip strength test (Jamar Hydraulic Hand Dynamometer; Sammons Preston, Bolingbrook, Illinois, USA), 6 min walk test (6MWT) 35 and sit-to-stand (STS) test. 36 The 6MWT will assess functional capacity in relation to activities of daily living. Constant work rate exercise test and 6MWT are complementary in the comprehensive evaluation of these patients. Nutritional status will be assessed by a registered dietitian using the Patient Generated Subjective Global Assessment, weight, body mass index, prealbumin and glycosylated hemoglobin (HbA1c). American Society of Anesthesiologists status, Charlson Comorbidity Index 37 and Euroscore II data will be recorded. Physical activity will be measured by the Yale Physical Activity Survey (YPAS), 39 functional capacity by Dukes Activity Status Index questionnaire 40 and Anxiety and depression measured using the Hospital and Anxiety Scale (HADS). 41 All patients will be reassessed using the same tests before undergoing cardiac surgery (T7) and at 3 months postoperatively (T9).

Procedures
Standard of care (T1–T6)
Participants in the control group will follow the standard preoperative protocol at Hospital Clinic de Barcelona that includes physical activity recommendation, nutritional and smoking cessation advice. Moreover, patients suffering from iron-deficiency anaemia will receive intravenous iron infusion. 42

Multimodal Prehabilitation programme (PreHab) (T1–T6)
Participants in the intervention group will undergo, in addition to the standard of care aforementioned, a 4–6 week personalised multimodal prehabilitation programme. The interventions included will be patient-centred aiming to optimise patients’ preoperative health status while enhancing their empowerment and engagement. The main components of the programme will consist in:

1. Supervised exercise training programme: 1-hour session, two sessions per week at the hospital outpatient gym facility conducted by a physiotherapist. Heart rate, blood pressure, oxygen saturation and perceived exertion rate using the modified Borg scale 45 will be monitored throughout the training session.
   i. Endurance training will be performed on stationary bicycle (Bike Forma; Technogym; Cesena, Italy) and will be tailored to the participants according to their PWR (baseline CPET). Each session includes 5 min of warm-up and 5 min of cool-down pedalling at 30%–40% of their PWR. An interval training consists in at least 5 bouts combining 2 min of moderate to high-intensity exercise (starting at 70% of PWR and progressing to
90%–100% of PWR throughout the programme interspersed with 3 min recovery periods at lower intensity (40%–50% of the PWR). Progression during the sessions will be tailored on individual basis to maximise the training effect.

ii. Strength training will consist in 2–3 upper (pectoralis and latissimus dorsi) and lower (quadriceps) limb exercises based on 2–3 sets of 8–12 repetitions avoiding valsalva’s manoeuvres. The training is performed in a modular training station using external load (Plurima Multistation Wall, Technogym; Cesena, Italy). At the first session, the physiotherapist obtains for each muscle group, the tolerated weight for the eight-repetition maximum test, to establish the initial weight for the strength training. The weight and/or the number of repetitions will increase every week to ensure strength progression and maximise the training effect. The strength training is performed 2 days per week (in combination with the endurance training).

2. Promotion of physical activity and healthy lifestyle: a physiotherapist adequately trained in behavioural strategies will use motivational interviewing techniques to promote physical activity and healthy lifestyle. The motivational interview will focus on empathy, reflective listening and affirmation, and will address the patients’ barriers and limitations related to physical activity, to get a change in behaviour.

3. Respiratory physiotherapy: patients will be instructed on daily breathing exercises (chest expansions, diaphragmatic respirations and deep inspirations) with a volumetric incentive spirometer (Coach 2; Smith Medical; London, UK), at least twice per day, 1–2 sets of 10–15 breathings for each exercise.

4. Nutrition counselling and supplementation: participants will meet with a registered dietitian that will assess their nutritional status and their diet based on a self-reported 3-day food diary. Nutritional teaching and a Mediterranean, well-balanced cardioprotective diet will be instructed. An adequate protein intake of 1.2–1.5 g/kg/day will be aimed to meet the European Society for Clinical Nutrition and Metabolism recommendations. If patient does not reach the recommended daily protein intake with diet, protein supplementation with whey protein (Fresubin Protein powder, Fresenius Kabi España) will be provided to reach the aforementioned daily protein intake.

5. Weekly mindfulness sessions: Patients will be invited to attend 1 weekly hourly session of Mindfulness-Based Stress Reduction conducted by a registered psychologist. It will be strongly recommended to those who reported high rates of anxiety and depression on the baseline HADS.

Compliance to the prehabilitation programme will be calculated counting the number of supervised sessions attended out of the total intended sessions. The occurrence of any exercise-related adverse events during the prehabilitation period will be recorded and will be reported immediately to the principal investigator.

Preoperative (T7) and 3-month postoperative functional assessment (T9)

All participants’ functional capacity will be reassessed before surgery and 3 months postoperative using ET, hand grip strength test, 6MWT and STS test. Anxiety and depression and physical activity questionnaires will be also recorded at these time points.

Surgery and hospital admission (T8)

Surgery will take place in the habitual waiting timeframe and will be performed by the regular cardiac surgery teams present in Hospital Clinic de Barcelona. Perioperative clinical protocols will be followed in a usual fashion independently of the group allocation or study participation. Hospital staff, anesthesiologists, surgeons, nurses and other people involved in patient care will be blinded to the study aim. Intraoperative complications or events as well as the need blood product transfusion or any deviation from normal course will be recorded in the intraoperative case report form (CRF).

Summary of flow chart is given in figure 1.

The primary outcome of this study is the incidence of postoperative complications before patient discharge from the hospital. The type of complications included will be classified following the standards of the European Society of Anesthesiology and the European Society of Intensive Care medicine. Acute kidney injury, acute respiratory distress syndrome, arrhythmia, cardiac arrest, cardiogenic pulmonary oedema, deep vein thrombosis, delirium, gastrointestinal bleed, infection, source uncertain, laboratory confirmed bloodstream infection, myocardial infarction, pneumonia, paralytic ileus, postoperative haemorrhage, pulmonary embolism, stroke, surgical site infection and urinary tract infection.

The severity of complications will be also recorded, as a secondary outcome measure, following the Clavien-Dindo classification. To ensure accuracy of the primary endpoint, the data will be collected by a physician member of the team, every day according to standard clinical care, and then reviewed by another researcher. Both of them will be blinded to the study group to avoid bias. Patient-chargeable costs (ie, pharmacy and blood bank); tariff-chargeable costs (ie, medical care, diagnostic techniques, laboratories, interconsultations); other healthcare resources use (ie, ICU stay, total hospitalisation length of stay, readmissions, emergency room visits) and survival will be also assessed at 3 months and 1 year postcardiac surgery by chart review.

Data collection management and monitoring

All participant’s de-identified data collected at different time points (table 1) will be entered by research staff members into Research Electronic Data Capture (REDCap) CRF via a secure webpage interface. Online data will be stored in a safe server located the Hospital.
Clinic facilities. All research team members will receive training on how to perform all the functional test included in the trial and how to input data in REDCap data manager.

Data monitoring
Previous experiences in prehabilitation studies show a clear absence of safety problems related to the experimental procedure. In addition, it is an unmasked trial, which is easier and faster to detect a problem and take appropriate measures.

The investigators of the present study are responsible for ensuring that the study meets the proposed milestones and deadlines. They will also be responsible for all aspects of the study design, management, ethical conduct, analysis and dissemination of results.

Safety data, including new hospitalisation, worsening angina or heart failure and arrhythmias, will be captured and all adverse events will be reported. They are responsible to periodically evaluate the study data for participant safety and study conduct, in addition to making modifications and/or termination of the trial after communication to the Ethics Committee of Clinical investigation of Hospital Clinic de Barcelona.

Outcomes
Clinical outcomes
The primary outcome variable of the study is the incidence of postoperative complications classified following the standards of the European Society of Anaesthesiology and European Society of intensive Care Medicine.46

Secondary outcome variables will be: (1) severity of postoperative complications using Dindo-Clavien classification; (2) hospital and ICU days of stay and (3) 3-month and 1-year mortality. Other outcome variables include: (1) ET measured by a cycling constant work-rate exercise testing at 80% of peak oxygen uptake; (2) distance covered in the 6MWT; (3) STS test and hand-grip strength; (4) physical activity by the YPAS and (5) hospitalisation direct costs and use of healthcare resources into the follow-up 1-year period after surgery.

Outcomes for feasibility of prehabilitation include incidence of adverse events during training, compliance to the supervised training sessions and adherence to the programme.

Statistical analyses
Sample size for this trial has been calculated based on the primary outcome of the study that is the reduction of incidence of postoperative complications in the prehabilitation group. Our own data in a similar population of patients indicated that the incidence of postoperative complications was 30%. Accepting a two-sided alpha-risk of 0.05 and beta-risk of 0.20, anticipating 10% of dropouts, indicated the need of including 80 participants per group to detect a reduction of the percentage of patients with complications in the intervention group compared with the control group 20%. No adjustment for multiplicity was proposed due to this is a clinical trial with one primary outcome and without needed of interim analyses.

This trial will use intention-to-treat criteria for main analysis; nevertheless, analysis per protocol will also be performed as supportive analysis. Categorical variables, as

Figure 1 Flow chart. CABG, coronary artery bypass grafting.
### Table 1  Study procedures and timeline

<table>
<thead>
<tr>
<th>Time point</th>
<th>Screening visit T(−1)</th>
<th>Baseline assessment T0</th>
<th>Multimodal prehabilitation 6 weeks T1–T6</th>
<th>Preoperative assessment T7</th>
<th>Surgery and admission T8</th>
<th>3 months postoperative T9</th>
<th>12 months postoperative T10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical evaluation</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening for trial eligibility</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient random allocation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Study groups

- Multimodal Prehab (PreHab)  
  - T1–T6: X
- Standard of Care (control)  
  - T0: X

#### Study tests and measurements

- **Demographics**  
  - X
- **Anthropometrics**  
  - X
- **Incremental CPET**  
  - X
- **Constant work-rate CPET**  
  - X
- **Prealbumin, albumin, Hb, HbA1c**  
  - X
- **6MWT**  
  - X
- **Sit to Stand test**  
  - X
- **Grip strength**  
  - X
- **YPAS**  
  - X
- **Compliance to prehab programme**  
  - X: T1–T6
- **HADS**  
  - X
- **Charlson Comorbidity Index**  
  - X
- **Euroscore II**  
  - X
- **Intraoperative complications**  
  - X
- **ICU stay**  
  - X
- **Length of stay**  
  - X
- **Postoperative complications**  
  - X
- **Reinterventions**  
  - X
- **Readmissions**  
  - X: T9, T10
- **Emergency room visits**  
  - X: T9, T10
- **Survival**  
  - X: T9, T10

CPET, cardiopulmonary exercise testing; HADS, Hospital and Anxiety Scale; ICU, intensive care unit; 6MWT, 6 min walk test; YPAS, Yale Physical Activity Survey.
well primary outcome, will be analysed with Fisher’s exact test. Continuous variables will be compared with Student’s t-test for independent groups and Mann-Whitney U test according to each variable distribution. Ordinal variables will be analysed by Mann-Whitney U test.

Secondary outcomes looking at the difference between groups for the change in functional capacity over the different time points (repeated measures) will be analysed using generalised estimating equations models and will be shown as estimated effect and their 95% CI. For these analyses, we will apply unstructured matrix in order to assess intra-subject correlation, for cases with no adjustments we will apply an autoregressive model (AR) (1) type matrix.

A cost-effectiveness study will be carried out from the perspective of the hospital, taking into account the costs of the intervention and the expenses related to the disease during the follow-up (30 days). For costs, the mean or median and their 95% CI of difference in per-patient costs between the two groups will be computed (control-group costs minus prehabilitation-group costs), so that positive values will be interpreted as savings of the prehabilitation programme. Considering previous experience with prehabilitation cost analysis, a highly skewed distribution will probably be present. Right-sided asymmetric distribution appears when some patients incur in high costs, mainly because of major medical complications. To deal with this, a non-parametric approach (bootstrapping) will be used. Bootstrap analysis yields more robust when dealing with skewed cost data compared with non-parametric tests.

Patient and public involvement
Patient and public involvement was taken into consideration for the development of this protocol. A satisfaction questionnaire was given to a sample of patients who had undergone a prehabilitation programme as part of their clinical pathway before an abdominal surgery. They gave feedback about both the assessments and interventions included in this trial. As a result of their feedback we proceeded to reduce the number of questionnaires given during the assessments, as well as an assessment and intervention redesign, resulting in a more flexible schedule for the participants.

ETHICS AND DISSEMINATION
Ethics approval for this trial has been obtained by the Ethics Committee of Clinical investigation of Hospital Clinic de Barcelona (HCB/2017/0708). This trial will be conducted according to the principles emanating from the Helsinki Declaration, with compliance to the Good Clinical Practice and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. Confidentiality for participants and their data will be guaranteed according to the Spanish data protection law ‘Ley Orgánica de Protección de Datos de Carácter Personal’ (15/1999, 13 diciembre) and the General Data Protection Regulation from the European Union (EU 2016/679).

All the explorations and tests in this trial are considered minimally invasive and are performed in presence of a physician under strict monitoring. The non-pharmacological characteristics of the intervention exclude the need for additional trial insurances.

Informed consent
To avoid contamination among groups, there will be two informed consents: all participants allocated in the control group will be proposed to participate in a study to investigate the relationship between cardiopulmonary reserve and postoperative outcomes and will sign the informed consent for the control group. All participants allocated in the intervention group will be proposed to participate in a study that investigates the effects of a multimodal prehabilitation programme on postoperative outcomes. Patients in the intervention group will sign the intervention group informed consent, where the intervention is defined. All potential participants will be given time to read the informed consent form, consider participation and ask doubts or questions regarding the study participation. If patient agrees to participate, he or she will be asked to provide written consent in the informed consent document. Participants will be free to withdraw their consent and opt out from the trial at any time without needing to explain the reason why. Withdrawal from the trial will not carry any prejudice in the participant care.

Author affiliations
1Anaesthesia and Intensive Care, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
2August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalunya, Spain
3Prehabilitation Unit, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
4Biostatistics Unit, Universitat Autonoma de Barcelona Facultat de Medicina, Bellaterra, Catalunya, Spain
5Respiratory Medicine, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
6Department of Cardiology, Cardiovascular Institute, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
7Department of Cardiac Surgery, Cardiovascular Institute, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
8Nutrition and Clinical Dietetics, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain


Funding Funding for the trial was provided by a grant from the Spanish Public Government Fondos de Investigación en Salud (FIS) Instituto Carlos III (PI17/00852), after a peer-reviewed process. The grant was awarded as a mean for the implementation of multimodal prehabilitation in cardiac surgery and the present trial is the main receiver of its funds along with a subproject of prehabilitation for cardiac transplant candidates. Protein supplementation with Fresubin Protein powder was provided and supported by Fresenius Kabi España.

Disclaimer The funding sources had no role in the design of this study and will not have any role during its execution, analyses or interpretation of the data.

Competing interests All researchers and authors of this protocol declare that they have no conflict of interest.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
REFERENCES


